Enabling Synthesis of ABBV-2222, A CFTR Corrector for the Treatment of Cystic Fibrosis.
Org Lett. 2019 Jul 01;:
Authors: Greszler SN, Shelat B, Voight EA
An enabling preclinical synthetic route to cystic fibrosis candidate ABBV-2222 is described. Two stereoselective steps provide access to an aminochroman intermediate with excellent control, and a late-stage demethylation/difluoromethylation sequence provides efficient access to the target molecule.
PMID: 31259557 [PubMed – as supplied by publisher]